We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Olix Pharmaceuticals

News List

Covid-19: Junshi Biosciences, OliX Pharmaceuticals explore drugs pharmaceutical-technology
March 24, 2020
Junshi Biosciences has partnered with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to co-develop neutralising antibodies for Covid-19 treatment.
OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics firstwordpharma
May 30, 2018
SUWON, South Korea, May 29, 2018 /PRNewswire/ -- OliX Pharmaceuticals Inc., a leading developer of RNA interference (RNAi) therapeutics (CEO: Dong-ki Lee, Ph.D.), announced that it received the Phase I clinical trial authorization (CTA) with its anti-scar